We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Genome-Wide cfDNA Analysis Detects Therapy Response in B-Cell Lymphoma

By LabMedica International staff writers
Posted on 10 Nov 2021
Diffuse large B-cell lymphoma (DLBCL) is the most common, aggressive type of non-Hodgkin lymphoma. More...
Although 50% to 60% of individuals achieve cure with chemoimmunotherapy, outcomes are poor for relapsed/refractory disease.

Chimeric antigen receptor (CAR) T-cell therapy represents breakthrough progress in personalized cancer therapy for patients with lymphoma. Low-coverage, genome-wide cell-free DNA measurements commonly used in noninvasive prenatal testing also appear useful in differentiating CAR T-cell therapy responders from non-responders among B-cell lymphoma patients.

Hematologists at the University of California San Diego (La Jolla, CA, USA) enrolled consecutive patients with relapsed/refractory B-cell lymphoma undergoing CAR T-cell therapy. Whole blood was collected from 12 patients undergoing CAR T-cell therapy for relapsed/refractory B-cell lymphoma. Samples were collected on standardized schedule of days. A total of 127 blood samples were processed to plasma and the buffy coat (cellular) component. For each blood sample, a plasma fraction and a buffy coat fraction were retained for subsequent testing. Scientists from Laboratory Corporation of America (Burlington, NC, USA) were part of the study group.

Cell-free DNA (cfDNA) from the plasma of each sample was extracted using a bead-based method. Libraries for genome-wide sequencing were created from cfDNA and sequencing was performed using HiSeq2500 instruments (Illumina, San Diego, CA, USA). Sequencing data were processed, and the genome instability number (GIN) was calculated. Total genomic DNA was extracted from the buffy coat using a column-based method (Qiagen, Venlo, The Netherlands). A ddPCR reaction was designed to quantify the abundance of the CAR construct and the human Ribonuclease P (RNAseP) gene using a QX200 droplet reader (Bio-Rad, Hercules, CA, USA).

The investigators reported that all five patients who remained in complete response (CR) at the time of last measurement had genomic instability number (GIN) <170 (threshold). Two patients who attained CR, but later relapsed, and all but one patient who had best response other than CR had last GIN measurement of >170. In five of six patients with relapsed or progressive disease, increasing GIN was observed prior to the diagnosis by imaging. The abundance of CAR T-cell construct (absolute number of construct copies relative to the number of human genome equivalents) also showed a trend to correlate with outcome by day 10.

Aaron M. Goodman, MD, a professor of medicine and the study's first author, said “This technology is perfect for lymphoma, explaining that cfDNA is an attractive means of monitoring lymphomas, as these cancers behave in some ways like solid tumors and feature cells that are often more sensitive to death and therefore to releasing nucleic acids into the bloodstream.”

The authors concluded that non-invasive liquid biopsy with cfDNA and copy number alterations (CNA) analysis may be correlated with response and may be utilized to monitor response in patients with relapsed B-cell lymphoma treated with CAR T-cell therapy. The study was published on October 13, 2021 in the journal Transplantation and Cellular Therapy.

Related Links:
University of California San Diego
Laboratory Corporation of America
Illumina
Qiagen
Bio-Rad



New
Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.